We use cookies on our website, which are text files containing small amounts of information that are downloaded to your computer or mobile device. To find out more about the cookies we use please click here.

Some of these cookies are strictly necessary for operation of this site. Other, non-essential cookies are used for measuring website performance (which is all aggregated and anonymised) and may share this information with Google. To consent to non-essential cookies, click "Accept all non-essential cookies".

Life Sciences & Bio-Sciences

This sector is headed by Investment Director Peter Dines, who is a specialist in growing businesses in the Life Sciences and Biosciences markets with the team’s key areas of focus including diagnostics, digital health, medical devices and synthetic biology.

The government’s Life Sciences Industrial Strategy published in 2017 by Sir John Bell, former President of the Academy of Medical Sciences, highlights the significant position of strength the UK has in the life sciences sector. A combination of a strong science base, a vibrant commercial sector in health and a comprehensive, engaged, data-rich healthcare system could provide an ideal environment for the UK to lead in many of these emerging areas of life sciences and to create successful new industries globally.

The life sciences industry represents one of the dominant economic sectors in the UK. ‘Health life sciences’ refers to the application of biology and technology, leading to health improvement, including biopharmaceuticals, medical technology, genomics, diagnostics and digital health. It has the advantage of very high productivity compared to other sectors and generates a wide range of products including drugs, medical technology, diagnostics and digital tools, as well as products for consumer health. It is also widely distributed across the whole of the UK and brings significant employment and economic growth to virtually every region.

In the coming decades, healthcare spending will surpass the economic growth in OECD countries by 3.3% versus 2.0% CAGR, creating a sustainability challenge for healthcare systems and new opportunities for life sciences industry growth. This is driven by macroeconomic factors such as an ageing population, a growing middle class and the increasing burden of chronic diseases that will accompany the significant change in demography. The global life sciences industry is expected to reach over $2.0trillion in gross value by 2023 (compared to approximately $1.6trillion today).

The UK is well positioned to lead in the discovery and evaluation of new technologies, including everything from patient records, X-rays, pathology, images, genomics, healthcare management tools, diagnostics, synthetic biology, digital monitoring and digital healthcare delivery that will fundamentally change the way we think about human illness and how best to manage it.

If your business operates in one of these sectors or you are looking for investment, then please do get in touch with the team today by completing this form.

If you would like to see more information about companies in this sector, then visit our portfolio page.

© Mercia Technologies 2019

Terms and conditions Privacy policy

Designed and built by Onespacemedia